13F Holdings
中文EN

VRCA Verrica Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1660334 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY370.2%
TTM net income YoY76.6%
TTM EPS YoY88.6%
Revenue 3-yr CAGR57.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-34.2%
Net margin-50.3%
FCF margin—
EBITDA margin-33.9%

Returns

ROE-240.4%
ROA-35.3%
ROIC (approx.)—
Asset turnover0.70x

Leverage & solvency

Liabilities / assets47.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-1.57x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$35.58M$7.57M$5.12M$9.03M$12.00M
Cost of revenue—$2.60M$500,000——
Gross profit—$4.97M$4.62M——
R&D expense$8.86M$11.84M$20.30M$12.20M$15.93M
SG&A expense$35.22M$58.82M$47.30M$17.41M$26.98M
Operating income-$12.19M-$65.92M-$65.76M-$21.30M-$30.91M
Interest expense$7.74M$9.41M$3.96M$2.17M$4.29M
Income tax$0$0$0$0—
Net income-$17.89M-$76.58M-$67.00M-$24.49M-$35.08M
EBITDA-$12.05M-$65.58M-$65.23M-$20.84M-$30.66M
EPS (basic)-1.68-14.78-1.48-0.72-1.30
EPS (diluted)-1.68-14.78-1.48-0.72-1.30
Weighted avg. shares (diluted)10.65M5.18M45.34M34.16M27.04M
Balance sheet
Cash & equivalents$30.15M$46.33M$69.55M$34.27M$15.75M
Short-term investments———$0$0
Receivables$5.26M$48,000$4.25M$0—
Inventory$2.24M$2.46M$1.02M$0—
Current assets$42.54M$51.18M$77.53M$39.12M$74.33M
PP&E, net$209,000$589,000$1.05M$3.89M$3.89M
Total assets$47.13M$54.13M$81.60M$44.72M$80.12M
Current liabilities$16.44M$29.01M$17.02M$3.46M$46.05M
Short-term debt$0$12.94M$0$0$41.69M
Long-term debt$0$30.98M$42.87M$0—
Total debt$0$43.92M$42.87M$0—
Total liabilities$22.39M$63.99M$61.83M$4.69M$47.52M
Shareholders' equity$24.74M-$9.86M$19.76M$40.03M$32.60M
Net debt-$30.15M-$2.41M-$26.67M-$34.27M—
Shares outstanding17.18M9.18M42.41M41.09M27.52M
Cash flow statement
Operating cash flow-$17.63M-$60.93M-$38.58M-$18.65M-$27.58M
Capital expenditure$0$27,000$362,000$302,000$883,000
Free cash flow-$17.63M-$60.95M-$38.94M-$18.95M-$28.46M
Investing cash flow$0-$19,000-$362,000$54.04M-$998,000
Financing cash flow$1.45M$37.73M$74.21M-$16.87M$33.65M
Depreciation & amortization$133,000$342,000$530,000$454,000$244,000
Stock-based compensation$3.32M$7.16M$14.38M$4.99M$6.05M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.